Enlaza Therapeutics Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers
Sept 2 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
ENLAZA THERAPEUTICS: STRATEGIC COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP WAR-LOCK DRUG CONJUGATES AND T-CELL ENGAGERS
ENLAZA: WILL RECEIVE $45 MILLION INCLUSIVE OF AN UPFRONT PAYMENT AND EQUITY INVESTMENT
ENLAZA: FURTHER ELIGIBLE TO RECEIVE MORE THAN $2 BILLION IN FUTURE MILESTONE PAYMENTS
ENLAZA: VERTEX WILL FUND ALL RESEARCH AND DEVELOPMENT COSTS RELATED TO FOUR-YEAR COLLABORATION
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

SpaceX IPO: Musk Weighs $60 Billion Cursor Deal, and Can It Save xAI?

Intel Q1 2026 Earnings Preview: The Rally is Ahead of the Fundamentals

SK Hynix Q1 2026 Earnings Preview: Memory Chip Prices Surge, Profit Set to Double

Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Tradingkey








